Jane Larkindale

About Jane Larkindale

Rare disease drug development specialist with a broad background in science, business and communications. Expertise across rare diseases and specialist knowledge in neuromuscular diseases including Duchenne muscular dystrophy, myotonic dystrophy and Friedreich’s ataxia. Translational and clinical development expertise, leading programs for two drugs from preclinical development through Phase 2 clinical trials. Launched and developed multiple international consortia to accelerate rare disease drug development through development of novel mathematical models, biomarkers and outcome measures. Experience with international regulatory agencies including scientific advice, investigational new drug applications and clinical trial applications.Collaborative scientist with a broad scientific background and experience driving projects to accelerate drug development for rare diseases. • Experience building and leading multi-stakeholder teams, including leading individual drug programs, driving progress from nonclinical through to global clinical trials• Program lead for a translational and clinical oligonucleotide program; built clinical infrastructure at company to support lead programs from nonclinical through to Phase 2 and designed pivotal studies.• Conceived of, initiated and led collaborative consortia including industry, academic researchers and regulators developing tools to support rare disease drug development (biomarkers, outcome measures, disease models and data and analytics platforms).• Extensive experience in working with global regulators on individual drug programs as well as through collaborative efforts to accelerate the development of therapies for rare diseases more broadly.• Rhodes Scholar, able to learn new skills and apply them to new situations, with scientific expertise across multiple disciplines including clinical research, regulatory science, genetics, biochemistry, molecular biology, neuroscience, neuromuscular disease, and informatics.

Experience

1. Vice President of Clinical Science

   PepGen

   Aug 2021 — Present · Boston, MA, US

   Program lead for a translational and clinical program in myotonic dystrophy• Leading trial design and interpretation of clinical data for first-in-human and Phase 2 studies of lead products for Duchenne muscular dystrophy and myotonic dystrophy• Responsible for endpoint and biomarker strategies for lead programs• Led early stage regulatory strategy and interactions (pre-IND meetings, scientific advice, initial CTAs, IND, etc.)• Leading translational research activities bridging between discovery, preclinical and clinical programs

Education

• University of Otago

  Bachelor's degree, Plant Biotechnology and Physics

• University of Oxford

  DPhil, Plant Science

Skills

• Business Development
• Philanthropy
• Contract Negotiation
• Drug Discovery
• Milestones
• New Business Development
• Nonprofits
• Research
• Biotechnology
• Venture Philanthropy
• Drug Development
• Biochemistry
• Genetics
• Non-Profits
• Clinical Trials
• Cell
• Life Sciences
• Translational Research
• Grants
• Program Management
• Lifesciences